6 recruiting, 1 active not recruiting. 3 Phase 2, 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 4 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
Follow Mild Autonomous Cortisol Secretion (MACS): new trials by email Literature Review of Mild Autonomous Cortisol Secretion (MACS) trials Research Report on Mild Autonomous Cortisol Secretion (MACS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 90 | 2026-10-01 | 2026-09-25 |
| Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion Tirzepatide, Standard medical treatment - Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status | Phase 2 | Recruiting | Alaa Sada | 34 | 2026-07-27 | 2026-07-30 |
| IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Intervention 1: Adrenalectomy, Intervention 2: Semaglutide - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 75 | 2026-03-05 | 2026-03-27 |
| Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS) Osilodrostat (Isturisa) - Mild Autonomous Cortisol Secretion (MACS) | Phase 4 | Recruiting | Johns Hopkins University | 10 | 2026-02-02 | 2026-10-23 |
| Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS) Metyrapone 250 mg Oral Tablets, Osilodrostat 1 MG, adrenalectomy - Mild Autonomous Cortisol Secretion (MACS) | Phase 4 | Recruiting | Laikο General Hospital, Athens | 150 | 2025-12-01 | 2025-12-05 |
| Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma Various labs and imaging tests - Mild Autonomous Cortisol Secretion (MACS) | Recruiting | The Cleveland Clinic | 20 | 2024-11-20 | 2026-01-08 | |
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS) Metyrapone - Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS) | Phase 2 | Active not recruiting | Mayo Clinic | 30 | 2023-12-19 | 2026-09-25 |
ACTH Syndrome, Ectopic (4) · Adrenal Hyperplasia, Congenital (3) · Cushing Syndrome (3) · Adrenal incidentaloma (1) · Hypertension (1) · Insulin Resistance (1) · Weight Loss (1)
Adrenal Gland Diseases (4) · Endocrine System Diseases (4) · Metabolic Diseases (4) · Neoplasms (4) · Nutritional and Metabolic Diseases (4) · Paraneoplastic Endocrine Syndromes (4) · Paraneoplastic Syndromes (4) · Adrenocortical Hyperfunction (3) · Adrenogenital Syndrome (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Disorders of Sex Development (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genetic Diseases, Inborn (3)
Metyrapone (3) · Osilodrostat (2) · Adrenalectomy (1) · Surgical Procedures, Operative (1) · Tirzepatide (1)
Mayo Clinic (2) · Alaa Sada (1) · Johns Hopkins University (1) · Laikο General Hospital, Athens (1) · The Cleveland Clinic (1) · University of Texas Southwestern Medical Center (1)
United States (6) · Greece (1)
Alaa Sada, MD (1) · Amir Hamrahian, MD (1) · Irina Bancos, MD (1) · Irina Bancos, MD, MS (1) · Ricardo Correa, MD (1)
PMID 27454103, PMID 28887710, PMID 29510982, PMID 30817193, PMID 31206616, PMID 35220871, PMID 3536461, PMID 35817047, PMID 36952249, PMID 37318239, PMID 37801655, PMID 39062179, PMID 39086899, PMID 6135282
K23DK142038 (1)